Plasma dispositions of ivermectin, doramectin and moxidectin following subcutaneous administration in rabbits.
This study evaluated the comparative plasma dispositions of ivermectin (IVM), doramectin (DRM) and moxidectin (MXD) following subcutaneous administration in rabbits. Fifteen New Zealand white rabbits were allocated into three groups of five animals each. The animals in each group received IVM, DRM or MXD by subcutaneous injection at a single dose of 0.3 mg/kg. Blood samples were collected at various times between 1 h and 40 days after treatment and the plasma samples were analysed by high-performance liquid chromatography using fluorescence detection. Moxidectin was absorbed faster from the injection site and reached the peak plasma concentration (C(max)) significantly earlier than IVM and DRM. There was no significant difference in C(max) values among the three molecules, whereas the area under the concentration-time curves of DRM (258.40 ng.d/mL) and IVM (191.62 ng.d/mL) was significantly higher than that of MXD (83.17 ng.d/mL). The mean plasma residence time and terminal half-life (t(1/2lambdaz)) were longer for DRM (7.52 and 4.48 days, respectively) and MXD (8.97 and 8.16 days, respectively) compared with IVM (4.73 and 2.75 days, respectively). Considering the pharmacokinetic parameters for the parent molecules, the persistence of DRM and MXD are significantly longer than IVM and this may have a positive effect on their efficacy in rabbits following subcutaneous administration or utility relating to interdosing interval.
Gokbulut
C
C
Department of Pharmacology and Toxicology, University of Adnan Menderes, Isikli Koyu, Aydin, Turkey. cgokbulut@adu.edu.tr
Biligili
A
A
Kart
A
A
Turgut
C
C
D000818:Animals; D000977:Antiparasitic Agents / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D019540:Area Under Curve; D002851:Chromatography, High Pressure Liquid; D005260:Female; D005453:Fluorescence; D006207:Half-Life; D007279:Injections, Subcutaneous; D007559:Ivermectin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000097:blood / Q000493:pharmacokinetics*; D018942:Macrolides / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics; D008297:Male; D011817:Rabbits
D000977:Antiparasitic Agents; D018942:Macrolides; D007559:Ivermectin; C084101:doramectin; C027837:moxidectin